21 reports

About ## percent of people who have food allergies are allergic to more than one food.

  • Cell Therapy
  • Medical Biotechnology
  • Oncology
  • Japan
  • Product Initiative

BIOLOGIC FOR CEDAR POLLEN ALLERGY - DRUG PROFILE OMALIZUMAB - DRUG PROFILE Drug Name Company/ Institute Name Licensed From Company Development Partner Product Description omalizumab F.

  • Cell Therapy
  • Oncology
  • Pharmaceutical
  • Japan
  • Product Initiative

THE DRUG CANDIDATE ACTS BY TARGETING DIPEPTIDASE-##.

  • Antifungal
  • Cell Therapy
  • Digestive System Disorder
  • Oncology
  • Bristol-Myers Squibb Company

The drug candidate is in Phase II stage for peanut allergy in adults and pediatrics, grass pollen allergy and dermatitis globally.

  • Antifungal
  • Cell Therapy
  • Digestive System Disorder
  • Oncology
  • United States

Patients were randomized in a ##:## fashion to active drug versus placebo.

  • Cell Therapy
  • Chronic Disease
  • Digestive System Disorder
  • Oncology
  • United States

The company offers drugs in the areas of nephrology, oncology, immunology and allergy, central nervous system among others.

  • Cell Therapy
  • Digestive System Disorder
  • Oncology
  • Therapy
  • United States

THE DRUG CANDIDATE IS A ## MER PEPTIDE ACTS BY TARGETING PROGRAMMED CELL DEATH ## LIGAND ## (PD-L##).

  • Blood Disease
  • Cell Therapy
  • Digestive System Disorder
  • Oncology
  • Bristol-Myers Squibb Company

The drug candidate is in Phase II stage for peanut allergy in adults and pediatrics, grass pollen allergy and dermatitis globally.

  • Antifungal
  • Cell Therapy
  • Digestive System Disorder
  • Oncology
  • United States

About ## percent of people who have food allergies are allergic to more than one food.

  • Cell Therapy
  • Digestive System Disorder
  • Monoclonal Antibody
  • Oncology
  • United States

Rituximab was well tolerated, and most adverse drug reactions were grade ##-## in severity.

  • Cell Therapy
  • Digestive System Disorder
  • Monoclonal Antibody
  • Oncology
  • United States

The molecules developed by Companies in Pre-Registration, Filing rejected/ Withdrawn, Phase III, Phase II, Phase I and Preclinical stages are ##, ##, ##, ##, ## and ## respectively.

  • Cell Therapy
  • Digestive System Disorder
  • Oncology
  • United States
  • Product Initiative

ABOUT ## PERCENT OF PEOPLE WHO HAVE FOOD ALLERGIES ARE ALLERGIC TO MORE THAN ONE FOOD.

  • Allergy Drug
  • Cell Therapy
  • Digestive System Disorder
  • Oncology
  • United States

THE DRUG CANDIDATE IS IN PHASE II STAGE FOR PEANUT ALLERGY IN ADULTS AND PEDIATRICS, GRASS POLLEN ALLERGY AND DERMATITIS GLOBALLY.

  • Cell Therapy
  • Digestive System Disorder
  • Oncology
  • United States
  • Product Initiative

The drug candidate targets P/ neurokinin ## (NK##) receptors.

  • Antifungal
  • Cell Therapy
  • Digestive System Disorder
  • Oncology
  • Helsinn Group

About ## percent of people who have food allergies are allergic to more than one food.

  • Cell Therapy
  • Digestive System Disorder
  • Oncology
  • Respiratory Disease
  • Regeneron Pharmaceuticals, Inc.

The drug candidate targets P/ neurokinin ## (NK##) receptors.

  • Antifungal
  • Cell Therapy
  • Digestive System Disorder
  • Oncology
  • Helsinn Group

About ## percent of people who have food allergies are allergic to more than one food.

  • Cell Therapy
  • Digestive System Disorder
  • Monoclonal Antibody
  • Oncology
  • Respiratory Disease

The company offers drugs in the areas of nephrology, oncology, immunology and allergy, central nervous system among others.

  • Cell Therapy
  • Digestive System Disorder
  • Monoclonal Antibody
  • Oncology
  • United States

This explains the need for a high drug dose of IXF-## as supported by the findings of the recently published post-hoc analysis.

  • Cell Therapy
  • Digestive System Disorder
  • Monoclonal Antibody
  • Oncology
  • United States

Two out of the six were considered possibly related to study drug: one in Group ## and one in Group ##.

  • Antifungal
  • Cell Therapy
  • Digestive System Disorder
  • Oncology
  • SCYNEXIS, Inc.

THE DRUG CANDIDATE IS IN PHASE II STAGE FOR PEANUT ALLERGY IN ADULTS AND PEDIATRICS, GRASS POLLEN ALLERGY AND DERMATITIS GLOBALLY.

  • Antifungal
  • Cell Therapy
  • Digestive System Disorder
  • Oncology
  • AstraZeneca PLC